KJ-C2320
/ CARsgen
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 14, 2025
KJ-C2320: Targeting CD38, for the treatment of acute myeloid leukemia (AML).
(Streetinsider.com)
- "An IIT has been initiated at the end of 2024."
Trial status • Acute Myelogenous Leukemia
January 20, 2025
CARsgen’s Allogeneic CD38 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial
(CARsgen Press Release)
- "CARsgen Therapeutics Holdings Limited...announces that KJ-C2320, an allogeneic CAR T-cell therapy targeting CD38, has administered the first dose to a patient in an investigator-initiated trial (IIT). KJ-C2320 is developed based on CARsgen’s THANK-uCAR platform. An investigator-initiated trial is ongoing in China to evaluate KJ-C2320 for the treatment of relapsed/refractory acute myeloid leukemia (R/R AML)."
Trial status • Acute Myelogenous Leukemia
1 to 2
Of
2
Go to page
1